Update on metastatic gastric and esophageal cancers

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1760-1769

  Shah, Manish A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADVANCED CANCER; ANGIOGENESIS; CANCER THERAPY; CARCINOGENESIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENOMICS; HUMAN; IMMUNOSURVEILLANCE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; ANIMAL; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; GENETICS; METABOLISM; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; SECONDARY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84937152729     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.1799     Document Type: Review

References (100)

1. Pennathur A, Gibson MK, Jobe BA, et al: Oesophageal carcinoma. Lancet 381:400-412, 2013
2. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
3. Santoro E: The history of gastric cancer: Legends and chronicles. Gastric Cancer 8:71-74, 2005
4. Guggenheim DE, Shah MA: Gastric cancer epidemiology and risk factors. J Surg Oncol 107: 230-236, 2013
5. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0: Cancer incidence and mortality worldwide - IARC CancerBase No. 11. http://globocan.iarc.fr
6. Jackson C, Cunningham D, Oliveira J, et al: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv34-iv36, 2009 (suppl 4)
7. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
8. Shah MA: Gastrointestinal cancer: Targeted therapies in gastric cancer - The dawn of a new era. Nat Rev Clin Oncol 11:10-11, 2014
9. Power DG, Kelsen DP, Shah MA: Advanced gastric cancer: Slow but steady progress. Cancer Treat Rev 36:384-392, 2010
10. Shah MA, Kelsen DP: Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 8:437-447, 2010
11. Shah MA, Khanin R, Tang LH, et al: Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 17:2693-2701, 2011
12. Fitzgerald RC, Hardwick R, Huntsman D, et al: Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436-444, 2010
13. Lynch HT, Grady W, Suriano G, et al: Gastric cancer: New genetic developments. J Surg Oncol 90:114-133, 2005
14. Huntsman DG, Carneiro F, Lewis FR, et al: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904-1909, 2001
15. Crew KD, Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol 12:354-362, 2006
16. Lichtenstein P, Holm NV, Verkasalo PK, et al: Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78-85, 2000
17. Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2:28-37, 2002
18. Schistosomes, liver flukes and Helicobacter pylori: IARC working group on the evaluation of carcinogenic risks to humans - Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61:1-241, 1994
19. Blaser MJ, Perez-Perez GI, Kleanthous H, et al: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 55:2111-2115, 1995
20. Hatakeyama M: Helicobacter pylori CagA and gastric cancer: A paradigm for hit-and-run carcinogenesis. Cell Host Microbe 15:306-316, 2014
21. Higashi H, Tsutsumi R, Muto S, et al: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295:683-686, 2002
22. Mueller D, Tegtmeyer N, Brandt S, et al: C-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest 122:1553-1566, 2012
23. Ohnishi N, Yuasa H, Tanaka S, et al: Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA105:1003-1008, 2008
24. Saito Y, Murata-Kamiya N, Hirayama T, et al: Conversion of Helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21. J Exp Med 207:2157-2174, 2010
25. Umeda M, Murata-Kamiya N, Saito Y, et al: Helicobacter pylori CagA causes mitotic impairment and induces chromosomal instability. J Biol Chem 284:22166-22172, 2009
26. Huang FY, Chan AO, Rashid A, et al: Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1b activation of nitric oxide production in gastric cancer cells. Cancer 118:4969-4980, 2012
27. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
28. Clemons NJ, Koh SY, Phillips WA: Advances in understanding the pathogenesis of Barrett's esophagus. Discov Med 17:7-14, 2014
29. Estores D, Velanovich V: Barrett esophagus: Epidemiology, pathogenesis, diagnosis, and management. Curr Probl Surg 50:192-226, 2013
30. Thrift AP, Pandeya N, Smith KJ, et al: Helicobacter pylori infection and the risks of Barrett's oesophagus: A population-based case-control study. Int J Cancer 130:2407-2416, 2012
31. Rudolph RE, Vaughan TL, Storer BE, et al: Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 132:612-620, 2000
32. Agrawal N, Jiao Y, Bettegowda C, et al: Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2:899-905, 2012
33. Dulak AM, Stojanov P, Peng S, et al: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45:478-486, 2013
34. Ilson DH: Esophageal cancer chemotherapy: Recent advances. Gastrointest Cancer Res 2:85-92, 2008
35. Wang J, Chang J, Yu H, et al: A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma in esophagus. Cancer Chemother Pharmacol 71:905-911, 2013
36. Conroy T, Galais MP, Raoul JL, et al: Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with esophageal cancer (PRODIGE5/ ACCORD17): Final results of a randomized, phase 2/3 trial. Lancet Oncol 15:305-314, 2014
37. Chau I, Norman AR, Cunningham D, et al: The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma: Individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20:885-891, 2009
38. Glimelius B, Ekström K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997
39. Murad A, Santiago F, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubiin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
40. Pyrhönen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
41. Scheithauer W, Kornek G, Zeh B, et al: Palliative Chemotherapy vs. Supportive Care in Patients With Metastatic Gastric Cancer: A Randomized Trial: Second International Conference on Biology, Prevention and Treatment of GI Malignancy. Koln, Germany, 1995 (abstr 68)
42. Ford HE, Marshall A, Bridgewater JA, et al: Docetaxel versus active symptom control for refractory oesophageal adenocarcinoma (COUGAR-02): An open-label, phase 3, randomised controlled trial. Lancet Oncol 15:78-86, 2014
43. Kang JH, Lee SI, Lim dH, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012
44. Thuss-Patience PC, Kretzschmar A, Deist T, et al: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27:211s, 2009 (suppl; abstr 4540)
45. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909, 2006
46. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006
47. Ridwelski K, Fahlke J, Kettner E, et al: Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. J Clin Oncol 26, 2008 (abstr 4512)
48. Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450-1457, 2008
49. Guimbaud R, Louvet C, Ries P, et al: Prospective, randomized, multicenter phase III study of fluorourcil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma fluorouracil: A French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32:3520-3526, 2014
50. Al-Batran SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26: 1435-1442, 2008
51. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
52. Kang YK, Kang WK, Shin DB, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as firstline therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 20:666-673, 2009
53. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 28:1547-1553, 2010
54. Yamada Y, Higuchi K, Nishikawa K, et al: Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol [epub ahead of print on October 14, 2014]
55. Ilson DH: Docetaxel, cisplatin, and fluorouracil in gastric cancer: Does the punishment fit the crime? J Clin Oncol 25:3188-3190, 2007
56. Lorenzen S, Hentrich M, Haberl C, et al: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Results of a phase II trial. Ann Oncol 18:1673-1679, 2007
57. Al-Batran SE, Hartmann JT, Hofheinz R, et al: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19:1882-1887, 2008
58. Tebbutt NC, Cummins MM, Sourjina T, et al: Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: The AGITG ATTAX trial. Br J Cancer 102:475-481, 2010
59. Shah MA, Stoller R, Shibata S, et al: Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol 28:304s, 2010 (suppl; abstr 4014)
60. Iacovelli R, Pietrantonio F, Farcomeni A, et al: Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systemic review and meta-analysis of published studies. PLoS One 9:e108940, 2014
61. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70-82, 2007
62. Bang YJ, Kim YW, Yang HK, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 379:315-321, 2012
63. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 52:797-805, 2008
64. Kyi C, Shah MA: A case report of trastuzumab dose in gastric cancer. J Gastrointest Oncol 4:E19-E22, 2013
65. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
66. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer: Guideline validation and development of standarized immunohistochemical testing. Virchows Arch 457:299-307, 2010
67. Tafe LJ, Janjigian YY, Zaidinski M, et al: Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: Correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 135:1460-1465, 2011
68. LoRusso PM, Weiss D, Guardino E, et al: Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437-6447, 2011
69. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER-2 positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
70. Lynce F, Swain SM: Pertuzumab for the treatment of breast cancer. Cancer Invest 32:430-438, 2014
71. Swain SM, Kim SB, Cortés J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA Study): Overall survival results from a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 14:461-471, 2013
72. Hecht JR, Bang YJ, Qin S, et al: Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 31:243s, 2013 (suppl 15s; abstr LBA4001)
73. Satoh T, Xu RH, Chung HC, et al: Lapatinib plus paclitaxel versus paclitaxel alone in the secondline treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-A randomized, phase III study. J Clin Oncol 32:2039-2049, 2014
74. Waddell T, Chau I, Cunningham D, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomized, open-label phase 3 trial. Lancet Oncol 14:481-489, 2013
75. Lordick F, Kang YK, Chung HC, et al: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomized, open-label phase 3 trial. Lancet Oncol 14:490-499, 2013
76. Ferrara N, Houck K, Jakeman L, et al: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18-32, 1992
77. Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469-478, 2006
78. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): An international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
79. Wilke H, Muro K, Van Custem E, et al: Ramicirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (RAINBOW): A double-blind randomised phase 3 trial. Lancet Oncol 15:1224-1235, 2014
80. Yoon HH, Bendell JC, Braiteh FS, et al: Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 32:256s, 2014 (suppl 15s; abstr 4004)
81. Qin S: Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 32:255s, 2014 (suppl 15s; abstr 4003)
82. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemohterapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011
83. Kang YK, Ohtsu A, Van Cutsem E, et al: AVAGAST: A randomized, double-blind, placebocontrolled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 28:302s, 2010 (suppl; abstr LBA4007)
84. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Onc 30:3499-3506, 2012
85. Ohigashi Y, Sho M, Yamada Y, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11:2947-2953, 2005
86. Lu B, Chen L, Liu L, et al: T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res 50:269-275, 2011
87. Kono K, Kawaida H, Takahashi A, et al: CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esopahgeal cancers. Cancer Immunol Immunother 55:1064-1071, 2006
88. Fife BT, Pauken KE: The role of PD-1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci 1217:45-59, 2011
89. Keir ME, Butte MJ, Freeman GJ, et al: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008
90. Segal NH, Antonia SJ, Brahmer JR, et al: Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 32:179s, 2014 (suppl 15s; abstr 3002)
91. Patnaik A, Kang SP, Tolcher AW, et al: Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 30:145s, 2012 (suppl 15s; abstr 2512)
92. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomized dose-comparison cohort of a phase I trial. Lancet 384:1109-1117, 2014
93. Muro K, Bang Y, Shankaran V, et al: A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients with advanced gastric cancer. Ann Oncol 25, 2014 (abstr LBA15)
94. Birchmeier C, Birchmeier W, Gherardi E, et al: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003
95. Graziano F, Galluccio N, Lorenzini P, et al: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789-4795, 2011
96. Bachleitner-Hofmann T, Sun MY, Chen CT, et al: HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 7:3499-3508, 2008
97. Lennerz JK, Kwak EL, Ackerman A, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810, 2011
98. Iveson T, Donehower RC, Davidenko I, et al: Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatmetn for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double blind, randomized phase 2 study. Lancet Oncol 15:1007-1018, 2014
99. Merchant M, Ma X, Maun HR, et al: Monovalent antibody design and mechanism of action of ornatuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 110:E2987-E2996, 2013
100. Spigel DR, Ervin TJ, Ramlau RA, et al: Randomized phase II trial of ornatuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105-4114, 2013